Avaliação Das Propriedades Elétricas De Barras Estatóricas Fabricadas Com Resina Do Tipo éter Diglicidílico Do Bisfenol F (dgebf) Contendo Nanopartículas De Silica

The present work aims to present the results of an application of a bisphenolic epoxy resin (DGEBF) containing silica nanoparticles (RN) and compare its properties with a bisphenolic epoxy resin (DGEBA) (RE), currently used. In this context, prototype stator bars for hydrogenerators were manufactured, according to the VPI (Vacuum-Pressure.Impregnation) system and their electrical properties with the tests of dissipation factor and voltage endurance. Within the results for the resins it was observed that: (i) dissipation factor and voltage endurance are practically the same for both resins; (ii) the resulting values of tip-up were 0.014% for RE and 0.020% for RN resin and (iii) the estimating of the life-time is about 40 years, what is suitable for most industrial applications. In this sense it is suggested that the RN resin can be an alternative to the RE resin, with an equivalent electrical performance.26326226

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types